{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"NSPR","limit":50},"count":50,"signals":[{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":33,"context":"incorporated by reference in the Registration Statement and the Prospectus, are independent public accountants as required by the Securities Act and the Public Accounting Oversight Board. (viii) *No Material Adverse Effect*. The Company and each of its significant subsidiaries as defined under Rule 102(w) of Regulation S-X (the **Subsidiaries**) (a complete list of the Subsidiaries is listed in Exhibit 21.1 to the Comp","filed_date":"2026-04-03","accession":"0001493152-26-015127","full_text":"https://origin.rootz.global/static/filing/0001493152-26-015127.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"IDE to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80 cm carotid stent system during transcarotid revascularization (TCAR) procedures. In the first quarter of 2026, we completed enrollment in the CGUARDIANS II pivotal study. In October 2023, the Centers for Medicare & Medicaid Services (CMS) issued its final National Coverage Determination (NCD), expanding coverage for both carotid","filed_date":"2026-03-18","accession":"0001493152-26-010886","full_text":"https://origin.rootz.global/static/filing/0001493152-26-010886.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":100,"match_count":5,"context":"ol systems, and misstatements due to error or fraud may occur and not be detected; | | |  |  |  | | |  |  |  we anticipate being subject to fluctuations in currency exchange rates because we expect a substantial portion of our revenues will be generated in Euros and U.S. dollars, while a significant portion of our expenses will be incurred in New Israeli Shekels; | | |  |  |  | | |  |  |  if there are significant shifts in the pol","filed_date":"2026-03-18","accession":"0001493152-26-010886","full_text":"https://origin.rootz.global/static/filing/0001493152-26-010886.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":69,"context":"nd security requirements. Violations of these laws can lead to civil and criminal penalties, including exclusion from participation in federal and state healthcare programs, any of which could have a material adverse effect on our business. These laws are potentially applicable to manufacturers of products regulated by the FDA as medical devices, such as us, and hospitals, physicians and other institutional or individua","filed_date":"2026-03-18","accession":"0001493152-26-010886","full_text":"https://origin.rootz.global/static/filing/0001493152-26-010886.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":21,"context":"ailed information with respect to the matters to be considered at the Annual Meeting. After careful consideration, **our board of directors recommends a vote FOR the election of the director nominees named in the Director Election Proposal (Proposal 1) and FOR the ratification of the re-appointment of Kesselman & Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers International Limited, as our","filed_date":"2025-04-15","accession":"0001641172-25-004800","full_text":"https://origin.rootz.global/static/filing/0001641172-25-004800.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"fficacy of the CGuard Carotid Stent System when used to treat symptomatic and asymptomatic carotid artery stenosis in patients undergoing carotid artery stenting (CAS). The study, which completed enrollment in June 2023, enrolled 316 patients across 24 trial sites in the U.S. and Europe and from April 2023 included deployment of the CGuard stent using CGuard Prime, our next generation CAS stent platf","filed_date":"2025-03-12","accession":"0001493152-25-009909","full_text":"https://origin.rootz.global/static/filing/0001493152-25-009909.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":100,"match_count":4,"context":"ol systems, and misstatements due to error or fraud may occur and not be detected; | | |  |  |  | | |  |  |  we anticipate being subject to fluctuations in currency exchange rates because we expect a substantial portion of our revenues will be generated in Euros and U.S. dollars, while a significant portion of our expenses will be incurred in New Israeli Shekels; | | |  |  |  | | |  |  |  if there are significant shifts in the pol","filed_date":"2025-03-12","accession":"0001493152-25-009909","full_text":"https://origin.rootz.global/static/filing/0001493152-25-009909.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":55,"context":"nd security requirements. Violations of these laws can lead to civil and criminal penalties, including exclusion from participation in federal and state healthcare programs, any of which could have a material adverse effect on our business. These laws are potentially applicable to manufacturers of products regulated by the FDA as medical devices, such as us, and hospitals, physicians and other institutional or individua","filed_date":"2025-03-12","accession":"0001493152-25-009909","full_text":"https://origin.rootz.global/static/filing/0001493152-25-009909.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":30,"context":"incorporated by reference in the Registration Statement and the Prospectus, are independent public accountants as required by the Securities Act and the Public Accounting Oversight Board. (viii) *No Material Adverse Effect*. The Company and each of its significant subsidiaries as defined under Rule 102(w) of Regulation S-X (the **Subsidiaries**) (a complete list of the Subsidiaries is listed in Exhibit 21.1 to the Comp","filed_date":"2024-05-31","accession":"0001493152-24-022222","full_text":"https://origin.rootz.global/static/filing/0001493152-24-022222.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":38,"context":"ailed information with respect to the matters to be considered at the Annual Meeting. After careful consideration, **our board of directors recommends a vote FOR the election of the director nominees named in the Director Election Proposal (Proposal 1), FOR the approval of the executive compensation that is described in the Say on Pay Proposal (Proposal 2), FOR the approval of holding an advisory vote every three year","filed_date":"2024-04-18","accession":"0001493152-24-015191","full_text":"https://origin.rootz.global/static/filing/0001493152-24-015191.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"fficacy of the CGuard Carotid Stent System when used to treat symptomatic and asymptomatic carotid artery stenosis in patients undergoing carotid artery stenting (CAS). The study, which completed enrollment in June 2023, enrolled 316 patients across 24 trial sites in the U.S. and Europe and from April 2023 included deployment of the CGuard stent using CGuard Prime, our next generation CAS stent platf","filed_date":"2024-03-05","accession":"0001493152-24-008850","full_text":"https://origin.rootz.global/static/filing/0001493152-24-008850.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":100,"match_count":4,"context":"ol systems, and misstatements due to error or fraud may occur and not be detected; | | |  |  |  | | |  |  |  we anticipate being subject to fluctuations in currency exchange rates because we expect a substantial portion of our revenues will be generated in Euros and U.S. dollars, while a significant portion of our expenses will be incurred in New Israeli Shekels; | | |  |  |  | | |  |  |  if there are significant shifts in the pol","filed_date":"2024-03-05","accession":"0001493152-24-008850","full_text":"https://origin.rootz.global/static/filing/0001493152-24-008850.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":56,"context":"nd security requirements. Violations of these laws can lead to civil and criminal penalties, including exclusion from participation in federal and state healthcare programs, any of which could have a material adverse effect on our business. These laws are potentially applicable to manufacturers of products regulated by the FDA as medical devices, such as us, and hospitals, physicians and other institutional or individua","filed_date":"2024-03-05","accession":"0001493152-24-008850","full_text":"https://origin.rootz.global/static/filing/0001493152-24-008850.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":16,"context":"ailed information with respect to the matters to be considered at the Annual Meeting. After careful consideration, **our board of directors recommends a vote FOR the election of the director nominees named in the Director Election Proposal (Proposal 1), FOR the approval of the potential issuance of shares in the Private Placement Proposal (Proposal 2), FOR the approval of the amendment to our Amended and Restated Cert","filed_date":"2023-07-28","accession":"0001493152-23-025891","full_text":"https://origin.rootz.global/static/filing/0001493152-23-025891.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"wo-sided 95% confidence interval calculated from the observed primary endpoint rate is < 11.6% and the p-value is less than 0.025. | -4- | | | | | On July 23, 2021, we announced the initiation of enrollment and successful completion of the first cases of our C-Guardian trial of CGuard EPS. These are 315 patients who are expected to be enrolled in the trial and receive CGuard EPS in the treatment of c","filed_date":"2023-03-30","accession":"0001493152-23-009598","full_text":"https://origin.rootz.global/static/filing/0001493152-23-009598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":100,"match_count":4,"context":"ystems, and misstatements due to error or fraud may occur and not be detected; | | | -27- | | | | | |  |  |  we anticipate being subject to fluctuations in currency exchange rates because we expect a substantial portion of our revenues will be generated in Euros and U.S. dollars, while a significant portion of our expenses will be incurred in New Israeli Shekels; | | |  |  |  | | |  |  |  if there are significant shifts in the pol","filed_date":"2023-03-30","accession":"0001493152-23-009598","full_text":"https://origin.rootz.global/static/filing/0001493152-23-009598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":41,"context":"nd security requirements. Violations of these laws can lead to civil and criminal penalties, including exclusion from participation in federal and state healthcare programs, any of which could have a material adverse effect on our business. These laws are potentially applicable to manufacturers of products regulated by the FDA as medical devices, such as us, and hospitals, physicians and other institutional or individua","filed_date":"2023-03-30","accession":"0001493152-23-009598","full_text":"https://origin.rootz.global/static/filing/0001493152-23-009598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":13,"context":"ed information with respect to the matters to be considered at the Annual Meeting. After careful consideration, **our board of directors recommends a vote FOR the election of the nominee for director named in the Director Election Proposal (Proposal 1) and FOR the ratification of the re-appointment of Kesselman & Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers International Limited, as our","filed_date":"2022-07-05","accession":"0001493152-22-018544","full_text":"https://origin.rootz.global/static/filing/0001493152-22-018544.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":26,"context":"nical events committee (CEC) adjudication and ipsilateral stroke from 31-365 day follow-up, based on Clinical Events Committee (CEC) adjudication. On July 23, 2021, we announced the initiation of enrollment and successful completion of the first cases of our C-Guardian trial of CGuard EPS. The first patients, who were under the care of principal investigator, Chris Metzger, M.D., system chair of clin","filed_date":"2022-03-07","accession":"0001493152-22-006180","full_text":"https://origin.rootz.global/static/filing/0001493152-22-006180.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":100,"match_count":4,"context":"our common stock may cause the price of our publicly traded securities to decline; | | |  |  |  | | |  |  |  we anticipate being subject to fluctuations in currency exchange rates because we expect a substantial portion of our revenues will be generated in Euros and U.S. dollars, while a significant portion of our expenses will be incurred in New Israeli Shekels; | | |  |  |  | | |  |  |  if there are significant shifts in the pol","filed_date":"2022-03-07","accession":"0001493152-22-006180","full_text":"https://origin.rootz.global/static/filing/0001493152-22-006180.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":38,"context":"nd security requirements. Violations of these laws can lead to civil and criminal penalties, including exclusion from participation in federal and state healthcare programs, any of which could have a material adverse effect on our business. These laws are potentially applicable to manufacturers of products regulated by the FDA as medical devices, such as us, and hospitals, physicians and other institutional or individua","filed_date":"2022-03-07","accession":"0001493152-22-006180","full_text":"https://origin.rootz.global/static/filing/0001493152-22-006180.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":26,"context":"| | |  |  (2) |  To consider and approve the Companys 2021 Equity Compensation Plan (the Incentive Plan Proposal). | | |  |  |  | | |  |  (3) |  An advisory vote on the compensation of the Companys named executive officers as disclosed in the Proxy Statement accompanying this notice (the Advisory Compensation Proposal). | | |  |  |  | | |  |  (4) |  Ratification of the appointment of Kesselman & Kesselman, Certified P","filed_date":"2021-08-12","accession":"0001493152-21-019508","full_text":"https://origin.rootz.global/static/filing/0001493152-21-019508.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":100,"match_count":4,"context":"our common stock may cause the price of our publicly traded securities to decline; | | |  |  |  | | |  |  |  we anticipate being subject to fluctuations in currency exchange rates because we expect a substantial portion of our revenues will be generated in Euros and U.S. dollars, while a significant portion of our expenses will be incurred in New Israeli Shekels; | | |  |  |  | | |  |  |  if there are significant shifts in the pol","filed_date":"2021-03-08","accession":"0001493152-21-005564","full_text":"https://origin.rootz.global/static/filing/0001493152-21-005564.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":30,"context":"nd security requirements. Violations of these laws can lead to civil and criminal penalties, including exclusion from participation in federal and state healthcare programs, any of which could have a material adverse effect on our business. These laws are potentially applicable to manufacturers of products regulated by the FDA as medical devices, such as us, and hospitals, physicians and other institutional or individua","filed_date":"2021-03-08","accession":"0001493152-21-005564","full_text":"https://origin.rootz.global/static/filing/0001493152-21-005564.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":100,"match_count":5,"context":"ers exercise their pre-funded warrants or Series G Warrants and acquire our common stock; | | ** ** |  |  |  we anticipate being subject to fluctuations in currency exchange rates because we expect a substantial portion of our revenues will be generated in Euros and U.S. dollars, while a significant portion of our expenses will be incurred in New Israeli Shekels; | | ** ** |  |  |  if there are significant shifts in the political,","filed_date":"2021-02-03","accession":"0001493152-21-002478","full_text":"https://origin.rootz.global/static/filing/0001493152-21-002478.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":30,"context":"immediately following this prospectus summary. These risks include, among others, the following: |  |  |  the COVID-19 pandemic has caused interruptions or delays of our business plan and may have a significant adverse effect on our business; | | |  |  |  | | |  |  |  we have a history of net losses and may experience future losses; | | |  |  |  | | |  |  |  the report of our independent registered public accounting firm","filed_date":"2021-02-03","accession":"0001493152-21-002478","full_text":"https://origin.rootz.global/static/filing/0001493152-21-002478.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":13,"context":"ders. Marvin Slosman and Thomas J. Kester are our Class 3 directors, with their terms of office to expire at our 2023 annual meeting of stockholders. At each annual meeting of stockholders, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election, with each director to hold office until his or her suc","filed_date":"2021-02-03","accession":"0001493152-21-002478","full_text":"https://origin.rootz.global/static/filing/0001493152-21-002478.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":100,"match_count":5,"context":"lders until such holders exercise their pre-funded warrants and acquire our common stock; | | ** ** |  |  |  we anticipate being subject to fluctuations in currency exchange rates because we expect a substantial portion of our revenues will be generated in Euros and U.S. dollars, while a significant portion of our expenses will be incurred in New Israeli Shekels; | | ** ** |  |  |  if there are significant shifts in the political,","filed_date":"2021-01-19","accession":"0001493152-21-001258","full_text":"https://origin.rootz.global/static/filing/0001493152-21-001258.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":30,"context":"immediately following this prospectus summary. These risks include, among others, the following: |  |  |  the COVID-19 pandemic has caused interruptions or delays of our business plan and may have a significant adverse effect on our business; | | |  |  |  | | |  |  |  we have a history of net losses and may experience future losses; | | |  |  |  | | |  |  |  the report of our independent registered public accounting firm","filed_date":"2021-01-19","accession":"0001493152-21-001258","full_text":"https://origin.rootz.global/static/filing/0001493152-21-001258.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":14,"context":"d information with respect to the matters to be considered at the Annual Meeting. After careful consideration, **our board of directors recommends a vote FOR the election of the nominees for director named in the Director Election Proposal (Proposal 1); FOR the Incentive Plan Proposal (Proposal 2); FOR the approval of the increase in the number of our authorized shares under the Authorized Share Capital Proposal (Prop","filed_date":"2020-07-17","accession":"0001493152-20-013519","full_text":"https://origin.rootz.global/static/filing/0001493152-20-013519.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":24,"context":"nd security requirements. Violations of these laws can lead to civil and criminal penalties, including exclusion from participation in federal and state healthcare programs, any of which could have a material adverse effect on our business. These laws are potentially applicable to manufacturers of products regulated by the U.S. Food and Drug Administration as medical devices, such as us, and hospitals, physicians and ot","filed_date":"2020-03-10","accession":"0001493152-20-003630","full_text":"https://origin.rootz.global/static/filing/0001493152-20-003630.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":22,"context":"to obtain additional financing on a timely basis, we may have to curtail our development activities and growth plans and/or be forced to sell assets, perhaps on unfavorable terms, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately could be forced to discontinue our operations and liquidate, in which event it is unlikely that stockholders would recei","filed_date":"2019-11-12","accession":"0001493152-19-016782","full_text":"https://origin.rootz.global/static/filing/0001493152-19-016782.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":21,"context":"nd security requirements. Violations of these laws can lead to civil and criminal penalties, including exclusion from participation in federal and state healthcare programs, any of which could have a material adverse effect on our business. These laws are potentially applicable to manufacturers of products regulated by the U.S. Food and Drug Administration as medical devices, such as us, and hospitals, physicians and ot","filed_date":"2019-02-19","accession":"0001493152-19-002225","full_text":"https://origin.rootz.global/static/filing/0001493152-19-002225.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":30,"context":"s may be granted to certain executive officers of the Company during any calendar year (the Plan Amendment Proposal) | | |  |  |  | | |  |  (3) |  An advisory vote on the compensation of the Companys named executive officers as disclosed in the Proxy Statement accompanying this notice. | | |  |  |  | | |  |  (4) |  An advisory vote on the frequency of future advisory votes on the compensation of the Companys named execu","filed_date":"2018-09-11","accession":"0001493152-18-013072","full_text":"https://origin.rootz.global/static/filing/0001493152-18-013072.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"to obtain additional financing on a timely basis, we may have to curtail our development activities and growth plans and/or be forced to sell assets, perhaps on unfavorable terms, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately could be forced to discontinue our operations and liquidate, in which event it is unlikely that stockholders would recei","filed_date":"2018-08-06","accession":"0001493152-18-011015","full_text":"https://origin.rootz.global/static/filing/0001493152-18-011015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"to obtain additional financing on a timely basis, we may have to curtail our development activities and growth plans and/or be forced to sell assets, perhaps on unfavorable terms, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately could be forced to discontinue our operations and liquidate, in which event it is unlikely that stockholders would recei","filed_date":"2018-05-07","accession":"0001493152-18-006329","full_text":"https://origin.rootz.global/static/filing/0001493152-18-006329.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"to obtain additional financing on a timely basis, we may have to curtail our development activities and growth plans and/or be forced to sell assets, perhaps on unfavorable terms, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately could be forced to discontinue our operations and liquidate, in which event it is unlikely that stockholders would recei","filed_date":"2018-02-13","accession":"0001493152-18-001974","full_text":"https://origin.rootz.global/static/filing/0001493152-18-001974.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":12,"context":"btain such additional financing on a timely basis, we may have to curtail our development activities and growth plans and/or be forced to sell assets, perhaps on unfavorable terms, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately could be forced to discontinue our operations and liquidate, in which event it is unlikely that stockholders would recei","filed_date":"2017-05-09","accession":"0001493152-17-004924","full_text":"https://origin.rootz.global/static/filing/0001493152-17-004924.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":14,"context":"btain such additional financing on a timely basis, we may have to curtail our development activities and growth plans and/or be forced to sell assets, perhaps on unfavorable terms, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately could be forced to discontinue our operations and liquidate, in which event it is unlikely that stockholders would recei","filed_date":"2017-02-16","accession":"0001493152-17-001710","full_text":"https://origin.rootz.global/static/filing/0001493152-17-001710.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":13,"context":"ownership of our common stock as of April 27, 2016 by: |  | | each person known by us to beneficially own more than 5.0% of our common stock; | | |  | | each of our directors; | | |  | | each of the named executive officers; and | | |  | | all of our directors and executive officers as a group. | | The percentages of common stock beneficially owned are reported on the basis of regulations of the Securities and Exchange","filed_date":"2016-05-04","accession":"0001615774-16-005197","full_text":"https://origin.rootz.global/static/filing/0001615774-16-005197.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"nited States, the U.S. Food and Drug Administration. Clinical trials are subject to rigorous regulatory requirements and are expensive and time-consuming to design and implement. They require the enrollment of a large number of patients, and suitable patients may be difficult to identify and recruit, which may cause a delay in the development and commercialization of our product candidates. In some t","filed_date":"2016-03-28","accession":"0001615774-16-004660","full_text":"https://origin.rootz.global/static/filing/0001615774-16-004660.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":16,"context":"btain such additional financing on a timely basis, we may have to curtail our development activities and growth plans and/or be forced to sell assets, perhaps on unfavorable terms, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately could be forced to discontinue our operations and liquidate, in which event it is unlikely that stockholders would recei","filed_date":"2016-03-28","accession":"0001615774-16-004660","full_text":"https://origin.rootz.global/static/filing/0001615774-16-004660.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":12,"context":"pbell Rogers, M.D. and James Barry, Ph.D. are our Class 3 directors, with their terms of office to expire at our 2017 annual meeting of stockholders. At each annual meeting of stockholders, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election, with each director to hold office until his or her suc","filed_date":"2016-03-28","accession":"0001615774-16-004660","full_text":"https://origin.rootz.global/static/filing/0001615774-16-004660.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"rt proposed a cash bonus target at the market 75th percentile, which was accepted by the compensation committee. Certain financial and operation metrics such as revenue, cash management, clinical enrollment and partnership targets were used in determining the final amount of such awards. We anticipate that similar metrics will be used in determining cash bonuses for 2015. | 23 | | | | | *Equity Based","filed_date":"2015-07-29","accession":"0001615774-15-001960","full_text":"https://origin.rootz.global/static/filing/0001615774-15-001960.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":45,"context":"ership of our common stock as of July 28, 2015 by: |  | | each person known by us to beneficially own more than 5.0% of our common stock; |  | |  |  |  each of our directors; | | |  |  |  each of the named executive officers; and | | |  |  |  all of our directors and executive officers as a group. | | The percentages of common stock beneficially owned are reported on the basis of regulations of the Securities and Exchan","filed_date":"2015-07-29","accession":"0001615774-15-001960","full_text":"https://origin.rootz.global/static/filing/0001615774-15-001960.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":46,"context":"12 in order to conduct a pivotal trial. On April 19, 2013, we received an approval with conditions from the U.S. Food and Drug Administration for our IDE application, which allowed us to initiate enrollment in the trial. This trial, which we refer to as the MASTER II trial, was expected to be a multi-center, randomized study, consisting of up to 1,114 patients suffering from STEMI throughout 35 sites","filed_date":"2015-03-12","accession":"0001144204-15-015698","full_text":"https://origin.rootz.global/static/filing/0001144204-15-015698.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":17,"context":"btain such additional financing on a timely basis, we may have to curtail our development activities and growth plans and/or be forced to sell assets, perhaps on unfavorable terms, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately could be forced to discontinue our operations and liquidate, in which event it is unlikely that stockholders would recei","filed_date":"2015-03-12","accession":"0001144204-15-015698","full_text":"https://origin.rootz.global/static/filing/0001144204-15-015698.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":39,"context":"pbell Rogers, M.D. and James Barry, Ph.D. are our Class 3 directors, with their terms of office to expire at our 2017 annual meeting of stockholders. At each annual meeting of stockholders, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election, with each director to hold office until his or her suc","filed_date":"2015-03-12","accession":"0001144204-15-015698","full_text":"https://origin.rootz.global/static/filing/0001144204-15-015698.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"| |  | | | |  | | | |  | 31 | % | |  | | | | ** ** |  | | All tangible long-lived assets are located in Israel. | | **NOTE 13 - SUBSEQUENT EVENTS:** As a result of the VFA, the Company suspended enrollment in the MASTER II trial, which had been previously launched to support its investigational device exemption application for MGuard Prime EPS with the U.S. Food and Drug Administration (FDA), pendin","filed_date":"2014-11-12","accession":"0001144204-14-067213","full_text":"https://origin.rootz.global/static/filing/0001144204-14-067213.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NSPR","company":"InspireMD, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":14,"context":"btain such additional financing on a timely basis, we may have to curtail our development activities and growth plans and/or be forced to sell assets, perhaps on unfavorable terms, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately could be forced to discontinue our operations and liquidate, in which event it is unlikely that stockholders would recei","filed_date":"2014-11-12","accession":"0001144204-14-067213","full_text":"https://origin.rootz.global/static/filing/0001144204-14-067213.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"2d8a38ddaa961be4c3e2cb3792963144fcbdc7ae70b1a688378f16c76fec851e","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"7d556a4a568c618e4f105b7d8d88c9661bb991ab74b02206ba5c2138fa105479","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":61,"hourly_limit":500,"remaining":439,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}